853 related articles for article (PubMed ID: 26725903)
1. Hepatitis B virus: new therapeutic perspectives.
Lin CL; Yang HC; Kao JH
Liver Int; 2016 Jan; 36 Suppl 1():85-92. PubMed ID: 26725903
[TBL] [Abstract][Full Text] [Related]
2. Review article: novel therapies for hepatitis B virus cure - advances and perspectives.
Lin CL; Kao JH
Aliment Pharmacol Ther; 2016 Aug; 44(3):213-22. PubMed ID: 27302653
[TBL] [Abstract][Full Text] [Related]
3. [The potential use of serum HBV RNA to guide the functional cure of chronic hepatitis B].
Lu FM; Wang J; Chen XM; Jiang JN; Zhang WH; Zhao JM; Ren H; Hou JL; Xia NS
Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):105-110. PubMed ID: 28297795
[TBL] [Abstract][Full Text] [Related]
4. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B.
Lai CL; Wong D; Ip P; Kopaniszen M; Seto WK; Fung J; Huang FY; Lee B; Cullaro G; Chong CK; Wu R; Cheng C; Yuen J; Ngai V; Yuen MF
J Hepatol; 2017 Feb; 66(2):275-281. PubMed ID: 27639844
[TBL] [Abstract][Full Text] [Related]
5. Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?
Alonso S; Guerra AR; Carreira L; Ferrer JÁ; Gutiérrez ML; Fernandez-Rodriguez CM
BMC Gastroenterol; 2017 Dec; 17(1):168. PubMed ID: 29268704
[TBL] [Abstract][Full Text] [Related]
6. New paradigms in hepatitis B management: only diamonds are forever.
Coffin CS; Lee SS
Br Med Bull; 2015; 116():79-91. PubMed ID: 26377741
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of the study of hepatitis B virus covalently closed circular DNA.
Kumar R; Pérez-Del-Pulgar S; Testoni B; Lebossé F; Zoulim F
Liver Int; 2016 Jan; 36 Suppl 1():72-7. PubMed ID: 26725901
[TBL] [Abstract][Full Text] [Related]
8. Future anti-HBV strategies.
Gane EJ
Liver Int; 2017 Jan; 37 Suppl 1():40-44. PubMed ID: 28052637
[TBL] [Abstract][Full Text] [Related]
9. New antivirals for the treatment of chronic hepatitis B.
Soriano V; Barreiro P; Benitez L; Peña JM; de Mendoza C
Expert Opin Investig Drugs; 2017 Jul; 26(7):843-851. PubMed ID: 28521532
[TBL] [Abstract][Full Text] [Related]
10. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
[TBL] [Abstract][Full Text] [Related]
11. Latest developments in the treatment of hepatitis B.
Dandri M; Petersen J
Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
[TBL] [Abstract][Full Text] [Related]
12. Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance.
Yang HC; Kao JH
Emerg Microbes Infect; 2014 Sep; 3(9):e64. PubMed ID: 26038757
[TBL] [Abstract][Full Text] [Related]
13. How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?
Wong GLH; Gane E; Lok ASF
J Hepatol; 2022 Jun; 76(6):1249-1262. PubMed ID: 35589248
[TBL] [Abstract][Full Text] [Related]
14. Current Status and Challenges in Anti-Hepatitis B Virus Agents Based on Inactivation/Inhibition or Elimination of Hepatitis B Virus Covalently Closed Circular DNA.
Zhuang AQ; Chen Y; Chen SM; Liu WC; Li Y; Zhang WJ; Wu YH
Viruses; 2023 Nov; 15(12):. PubMed ID: 38140556
[TBL] [Abstract][Full Text] [Related]
15. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus.
Durantel D; Zoulim F
J Hepatol; 2016 Apr; 64(1 Suppl):S117-S131. PubMed ID: 27084032
[TBL] [Abstract][Full Text] [Related]
16. The current status and future directions of hepatitis B antiviral drug discovery.
Tang L; Zhao Q; Wu S; Cheng J; Chang J; Guo JT
Expert Opin Drug Discov; 2017 Jan; 12(1):5-15. PubMed ID: 27797587
[TBL] [Abstract][Full Text] [Related]
17. Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics.
Guo JT; Guo H
Antiviral Res; 2015 Oct; 122():91-100. PubMed ID: 26272257
[TBL] [Abstract][Full Text] [Related]
18. Cellular DNA Topoisomerases Are Required for the Synthesis of Hepatitis B Virus Covalently Closed Circular DNA.
Sheraz M; Cheng J; Tang L; Chang J; Guo JT
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867306
[TBL] [Abstract][Full Text] [Related]
19. Effects of entecavir on hepatitis B virus covalently closed circular DNA in hepatitis B e antigen-positive patients with hepatitis B.
Shi M; Sun WL; Hua YY; Han B; Shi L
PLoS One; 2015; 10(2):e0117741. PubMed ID: 25647607
[TBL] [Abstract][Full Text] [Related]
20. T5 Exonuclease Hydrolysis of Hepatitis B Virus Replicative Intermediates Allows Reliable Quantification and Fast Drug Efficacy Testing of Covalently Closed Circular DNA by PCR.
Qu B; Ni Y; Lempp FA; Vondran FWR; Urban S
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
